Market capitalization | $215.29m |
Enterprise Value | $245.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.75 |
P/S ratio (TTM) P/S ratio | 3.28 |
P/B ratio (TTM) P/B ratio | 7.73 |
Revenue growth (TTM) Revenue growth | 48.91% |
Revenue (TTM) Revenue | $65.56m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
6 Analysts have issued a Biodesix Inc forecast:
6 Analysts have issued a Biodesix Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 66 66 |
49%
49%
|
|
Gross Profit | 51 51 |
64%
64%
|
|
EBITDA | -29 -29 |
34%
34%
|
EBIT (Operating Income) EBIT | -35 -35 |
29%
29%
|
Net Profit | -44 -44 |
31%
31%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
Head office | United States |
CEO | Scott Hutton |
Employees | 217 |
Founded | 2005 |
Website | www.biodesix.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.